.jpg)
.png)
...the times they are a-changin' ~Bob Dylan
These are exciting times for Lipidologists! We can always count on change as the one sure thing in life.
Article By:
Clinical Epidemiology and Biostatistics and
Clinical Lipidology Professor
Oklahoma University Health Sciences Center
Oklahoma City, OK
Diplomate, American Board of Clinical Lipidology
I am pleased to present to the National Lipid Association the Spring 2013 issue of the Lipid Spin. The Pacific Lipid Association serves the states of Washington, Oregon, California, Idaho, Montana, Nevada, Utah, Alaska, and Hawaii.
Article By:
Pacific Lipid Association President
Director, Preventive Cardiology and Cardiovascular Rehabilitation
Director, Lipid Clinic and LDL Apheresis Program
Chair, Department of Cardiology
Saint Alphonsus Regional Medical Center
Boise, ID
Diplomate, American Board of Clinical Lipidology
The NLA has consistently held a determined focus on promoting the highest levels of education and professional development. We are defined by the quality of our outstanding leadership, members, partners and staff. As a result, we are continuously challenged to assess and refine our work in an attempt to produce the best and most innovative programming in Clinical Lipidology, leading to a direct and measurable impact in our medical community and across the globe.
Article By:
President, National Lipid Association
Director of Preventative Cardiology
CGH Medical Center, Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois School of Medicine, Peoria, IL
Diplomate, American Board of Clinical Lipidology
Please help us gain insight into the use of plaque information obtained from coronary CTA in managing your patients by participating in “Potential Clinical Applications of Plaque Imaging by CTA: A Survey,” conducted by Harvey Hecht and Jagat Narula from Mount Sinai Medical Center and Stephan Achenbach from The University of Erlangen.
The answer sheet to the survey is available at the end of the document.
When Tara Dall, MD, began her medical career, it was in 2001, after she graduated from medical school and completed her residency at the University of Wisconsin at Madison. She started as a family practice physician with no specialization in lipidology. That changed quickly, however, when she saw how much lipid management impacted her patients’ everyday lives.
Article By:
Medical Director/President
Advanced Lipidology
Delafield, WI
Diplomate, American Board of Clinical Lipidology
This 58-year-old patient was referred to the lipid clinic for statin intolerance and a history of "genetic hypercholesterolemia." The patient has had tendon xanthomas on the extensor surface of his hands and on his Achilles tendons since childhood just like his brother and sister. Both siblings have expired prematurely due to coronary artery disease.
Article By:
President, Midwest Lipid Association
Director, Midwest Heart Disease Prevention Center
Assistant Professor, Loyola Stritch School of Medicine
Naperville, IL
Diplomate, American Board of Clinical Lipidology
Familial hypercholesterolemia (FH) is a disease caused by autosomal dominant defects in the genes coding for the lowdensity lipoprotein (LDL) receptor, apolipoprotein (Apo) B, or proprotein convertase subtilisin/kexin type 9 (PCSK9).1 It is the most common single gene lipid disorder. FH is characterized by severely elevated blood cholesterol concentrations.
Article By:
Biofortis Clinical Research
Addison, IL
Diplomate, American Board of Clinical Lipidology
Biofortis Clinical Research
Addison, IL
Over 26 million Americans have chronic kidney disease (CKD). At risk for CKD include 65 million Americans with hypertension and 20 million patients with diabetes mellitus. The risk of cardiovascular disease (CVD), including coronary, cerebrovascular, peripheral vascular disease, and congestive heart failure increases by 3-to-20-fold as CKD progresses.
Article By:
Advanced Lipidology
Delafield, WI
Diplomate, American Board of Clinical Lipidology
The primary health care of women is a complex world of "Hearts, Hormones, Ovaries, Breasts and Bones." Over the past year women have expressed concern when reading articles and listening to media reports that suggest taking calcium supplements may help prevent fractures but at the same time may increase their risk for cardiovascular events. The Nurses' Health Study reported calcium supplement intake increased from 30% in 1984 to 72% in 2004.
Article By:
Director of Women's Health
Minot Health and Wellness
Minot, ND
On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi company. The mipomersen clearance follows a 9-6 vote in favor of the drug's approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee this past October.